MOH: Cup Handle detected on 7 Jul 2026

MOH is forming a cup-handle pattern with current price at $227.70, trading near the handle resistance at $203.06 after a strong 3-month rally of +63.37%. The pattern displays moderate quality with structure score of 12.0, breakout score of 13.0, and volume score of 10.5 (volume ratio 0.75 vs. 20-day average). Price sits 88% above its 52-week low, suggesting a mature advance. The overall score of 76.5 reflects a solid but not exceptional setup. RSI at 70.14 indicates overbought conditions, while positive MACD histogram (+2.0954) supports directional momentum.

Molina Healthcare reported Q1 2026 earnings on April 22, 2026, posting adjusted EPS of $2.35, which exceeded analyst expectations of $1.79 by 31.28%. However, the earnings story is layered with headwinds. A $93M impairment related to exiting its Medicare Advantage Prescription Drug product for 2027 compressed earnings, while premium revenue declined 4% to $10.2B due to lower Medicaid membership from market contraction and the Virginia Medicaid contract expiration. The company reaffirmed full-year 2026 guidance of approximately $42 billion in premium revenue and at least $5 in adjusted earnings per share. The next earnings report is scheduled for July 22, 2026, with analysts projecting an EPS of $1.42. Recent strength may reflect relief from Q1 beat and guidance reaffirmation, though structural Medicaid headwinds remain.

A successful breakout above the $203.06 handle resistance would target $242.87 conservative, representing 6.7% upside from current levels. Volume confirmation would be critical—the pattern needs current volume of 823K to exceed the 20-day average of 1.09M to validate breakout conviction. Invalidation occurs at the key support level of $192.50, approximately 15.5% below current price. The 54.49% win probability suggests coin-flip odds, below the 55%+ threshold for high-conviction setups. Overbought RSI (70) raises caution on immediate follow-through.

Medicaid membership attrition is expected to increase to 6% for the year, up from previous guidance of a 2% decline—a significant deterioration signaling structural headwinds. The company is exiting the MAPD product for 2027, which is expected to result in a $1 EPS drag for 2026. The company faces challenges in Medicaid work requirements and redeterminations, plus uncertainty around regulatory changes in the Marketplace segment for the 2027 pricing cycle. RSI at 70.14 signals overbought conditions with limited near-term upside cushion. Earnings date on July 22, 2026 (15 days out) poses execution risk given elevated member attrition expectations. Negative beta (-0.58) suggests stock may underperform if broader healthcare weakness develops.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.